Table III.
Distribution and survival associations of serum PAR-1 levels on the clinical parameters in gastric cancer patients.
| Serum PAR-1 level, P-value | ||
|---|---|---|
| Parameters | Distribution | Survival |
| Age, years | 0.06 | 0.61 |
| <60/≥60 | ||
| Gender | 0.59 | 0.56 |
| Male/female | ||
| Localization of tumor | 0.10 | 0.04 |
| Cardia/antrum | ||
| Histology | 0.27 | 0.22 |
| Adenocarcinoma/signet ring | ||
| Grade | 0.41 | 0.10 |
| I–II/III | ||
| Tumor (T) stage | 0.12 | 0.06 |
| 1–3/4 | ||
| No. of involved lymph node | 0.57 | 0.21 |
| 0–2/≥3 | ||
| Curative surgery | 0.46 | 0.36 |
| Yes/no | ||
| Metastasis | 0.99 | 0.03 |
| Yes/no | ||
| Liver metastasis | 0.38 | 0.11 |
| Yes/no | ||
| Hemoglobin level | 0.23 | 0.34 |
| Low/normal | ||
| WBC count | 0.06 | 0.30 |
| High/normal | ||
| Platelet count | 0.68 | 0.51 |
| High/normal | ||
| ESR | 0.97 | 0.02 |
| High/normal | ||
| LDH level | 0.70 | 0.11 |
| High/normal | ||
| CEA level | 0.66 | 0.01 |
| High/normal | ||
| CA 19–9 level | 0.92 | 0.04 |
| High/normal | ||
| Chemotherapy responsiveness | 0.43 | 0.05 |
| Yes/no | ||
| Serum PAR-1 level | – | 0.27 |
| Median, < or ≥ | ||
PAR-1, protease-activated receptor-1; WBC, white blood cell; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; CEA, carcinoembryonic antigen; CA 19–9, carbohydrate antigen 19–9.